HRTXHeron Therapeutics, Inc.

$162M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$38M+16.5% YoY

Gross Profit

$23M59.7% margin

Operating Income

-$4M-10.7% margin

Net Income

-$17M-45.8% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

+2.7%

Cash Flow

Operating Cash Flow

$1M

Free Cash Flow

$1M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$249M

Total Liabilities

$234M

Stockholders' Equity

$15M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38M	$33M	+16.5%
Gross Profit	$23M	$23M	-2.2%
Operating Income	-$4M	-$4M	+8.2%
Net Income	-$17M	-$5M	-260.9%

Revenue Segments

C I N V A N T I

$24M68%

Z Y N R E L E F

$9M26%

S U S T O L

$2M5%

HRTX Q3 2025 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena